S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.46 (+1.16%)
AAPL   110.24 (+1.87%)
MSFT   206.38 (+1.57%)
FB   251.27 (+0.70%)
GOOGL   1,427.55 (+0.33%)
AMZN   3,044.50 (+0.82%)
TSLA   405.44 (+4.55%)
NVDA   504.85 (+2.21%)
BABA   267.24 (-0.92%)
CGC   13.97 (-2.10%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.62 (+1.06%)
T   27.83 (-0.75%)
F   6.54 (-1.80%)
ACB   5.00 (-3.85%)
GILD   62.00 (-0.40%)
NFLX   477.06 (+0.84%)
DIS   122.63 (+0.11%)
BAC   23.30 (-0.17%)
BA   151.28 (+3.58%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.46 (+1.16%)
AAPL   110.24 (+1.87%)
MSFT   206.38 (+1.57%)
FB   251.27 (+0.70%)
GOOGL   1,427.55 (+0.33%)
AMZN   3,044.50 (+0.82%)
TSLA   405.44 (+4.55%)
NVDA   504.85 (+2.21%)
BABA   267.24 (-0.92%)
CGC   13.97 (-2.10%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.62 (+1.06%)
T   27.83 (-0.75%)
F   6.54 (-1.80%)
ACB   5.00 (-3.85%)
GILD   62.00 (-0.40%)
NFLX   477.06 (+0.84%)
DIS   122.63 (+0.11%)
BAC   23.30 (-0.17%)
BA   151.28 (+3.58%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.46 (+1.16%)
AAPL   110.24 (+1.87%)
MSFT   206.38 (+1.57%)
FB   251.27 (+0.70%)
GOOGL   1,427.55 (+0.33%)
AMZN   3,044.50 (+0.82%)
TSLA   405.44 (+4.55%)
NVDA   504.85 (+2.21%)
BABA   267.24 (-0.92%)
CGC   13.97 (-2.10%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.62 (+1.06%)
T   27.83 (-0.75%)
F   6.54 (-1.80%)
ACB   5.00 (-3.85%)
GILD   62.00 (-0.40%)
NFLX   477.06 (+0.84%)
DIS   122.63 (+0.11%)
BAC   23.30 (-0.17%)
BA   151.28 (+3.58%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.46 (+1.16%)
AAPL   110.24 (+1.87%)
MSFT   206.38 (+1.57%)
FB   251.27 (+0.70%)
GOOGL   1,427.55 (+0.33%)
AMZN   3,044.50 (+0.82%)
TSLA   405.44 (+4.55%)
NVDA   504.85 (+2.21%)
BABA   267.24 (-0.92%)
CGC   13.97 (-2.10%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.62 (+1.06%)
T   27.83 (-0.75%)
F   6.54 (-1.80%)
ACB   5.00 (-3.85%)
GILD   62.00 (-0.40%)
NFLX   477.06 (+0.84%)
DIS   122.63 (+0.11%)
BAC   23.30 (-0.17%)
BA   151.28 (+3.58%)
Log in
NASDAQ:CVAC

CureVac B.V. Stock Forecast, Price & News

$44.65
+0.85 (+1.94 %)
(As of 09/25/2020 11:40 AM ET)
Add
Compare
Today's Range
$43.80
Now: $44.65
$45.80
50-Day Range N/A
52-Week Range
$36.15
Now: $44.65
$85.00
Volume6,092 shs
Average Volume1.91 million shs
Market Capitalization$7.86 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Read More
CureVac B.V. logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CVAC
CUSIPN/A
CIKN/A
Phone49-70-71988-30

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7.86 billion
Next Earnings DateN/A
OptionableNot Optionable
$44.65
+0.85 (+1.94 %)
(As of 09/25/2020 11:40 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVAC News and Ratings via Email

Sign-up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CureVac B.V. (NASDAQ:CVAC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of CureVac B.V.?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac B.V. in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CureVac B.V.
.

What price target have analysts set for CVAC?

4 brokers have issued 12 month target prices for CureVac B.V.'s stock. Their forecasts range from $58.00 to $70.00. On average, they anticipate CureVac B.V.'s share price to reach $66.50 in the next year. This suggests a possible upside of 48.9% from the stock's current price.
View analysts' price targets for CureVac B.V.
.

Who are some of CureVac B.V.'s key competitors?

What other stocks do shareholders of CureVac B.V. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac B.V. investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), Novavax (NVAX), Gilead Sciences (GILD), Pfizer (PFE), AstraZeneca (AZN), Vaxart (VXRT), Johnson & Johnson (JNJ), Rocket Companies (RKT) and Tesla (TSLA).

When did CureVac B.V. IPO?

(CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

What is CureVac B.V.'s stock symbol?

CureVac B.V. trades on the NASDAQ under the ticker symbol "CVAC."

When did the company's quiet period expire?

CureVac B.V.'s quiet period expired on Wednesday, September 23rd. CureVac B.V. had issued 13,333,333 shares in its IPO on August 14th. The total size of the offering was $213,333,328 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of CureVac B.V.?

Shares of CVAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CureVac B.V.'s stock price today?

One share of CVAC stock can currently be purchased for approximately $44.65.

How big of a company is CureVac B.V.?

CureVac B.V. has a market capitalization of $7.86 billion.

What is CureVac B.V.'s official website?

The official website for CureVac B.V. is www.curevac.com.

How can I contact CureVac B.V.?

CureVac B.V.'s mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company can be reached via phone at 49-70-71988-30 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.